Import from '@womanrx/ui'

Heart Rate Variability (HRV) and Medication-Driven Changes: A Women's Guide

What HRV Actually Measures, and Why It Matters More for Women

HRV is the beat-to-beat variation in the interval between consecutive heartbeats. A higher HRV generally signals that your autonomic nervous system (ANS) is flexible enough to shift quickly between its parasympathetic ("rest and digest") and sympathetic ("fight or flight") branches. Low HRV is linked to worse cardiovascular outcomes, higher all-cause mortality, and impaired recovery from physical and psychological stress 1.

Women are not simply smaller men from an autonomic standpoint. Sex differences in ANS regulation are well-documented. Premenopausal women show higher vagal (parasympathetic) tone than age-matched men, an advantage tied to estrogen's direct effect on cardiac muscarinic receptors 2. That advantage is real but age-dependent: it narrows during perimenopause and largely disappears by postmenopause.

The Two Numbers You Will See Most Often

Most consumer wearables and clinical reports focus on two HRV metrics:

• rmsSD (root mean square of successive differences): reflects beat-to-beat parasympathetic activity; the most reproducible short-term metric
• SDNN (standard deviation of all NN intervals): reflects total ANS variability, usually from a 24-hour recording

For daily tracking, rmsSD is what matters. For cardiovascular risk stratification after MI, clinicians lean on 24-hour SDNN, where a value below 50 ms predicts substantially higher mortality 1.

How Your Menstrual Cycle Changes the Numbers

Your HRV is not a fixed biomarker. It moves across your cycle. Studies using 24-hour Holter monitors show that HF (high-frequency) power, the parasympathetic component, peaks in the mid-luteal phase alongside progesterone's rise, while LF/HF ratio, a sympatho-vagal balance index, increases during the late follicular phase when estrogen is highest 3.

Practically: if you measure your HRV daily and see a dip around day 14 or again around day 25-27, that is physiology, not a problem. Tracking relative changes within your own cycle is far more informative than comparing a single reading against a population norm.

What Counts as a Normal or Optimal HRV for a Woman?

There is no single universal "normal." Optimal HRV is always relative to your age, fitness, and life stage. The ranges below come from the Task Force on HRV 1 and subsequent normative data studies.

Age-Stratified rmsSD Reference Ranges in Women

| Age Group | rmsSD (ms), approximate | Notes | |---|---|---| | 20-29 yr | 40-90 | Higher in athletes | | 30-39 yr | 35-80 | Slight decline begins | | 40-49 yr | 25-60 | Perimenopausal decline often starts here | | 50-59 yr | 20-50 | Drops sharply around final menstrual period | | 60+ yr | 15-40 | Further autonomic aging |

These are approximations. A large normative dataset from the UK Biobank found that women's SDNN declines by roughly 1.5-2 ms per decade before menopause, then accelerates by an additional 15-20% in the two years surrounding the final menstrual period 4.

What "Optimal" Means in Practice

"Optimal" for you is your own highest consistent baseline, measured at the same time each morning, under the same conditions (supine, before coffee, after a full night of sleep). Chasing a published population norm misses the point. The WHOOP and Garmin algorithms use this individualized approach explicitly, anchoring your daily HRV against your personal rolling 30-60-day average rather than a fixed number.

For cardiovascular risk, a 24-hour SDNN below 50 ms is the clinically validated threshold associated with increased all-cause and cardiac mortality in post-MI populations 1. Women in the Framingham Heart Study who were in the lowest HRV quartile had a significantly elevated risk of cardiac events even after controlling for traditional risk factors 5.

How Medications Change HRV: A Drug-by-Drug Breakdown for Women

Many prescription medications alter HRV directly, by changing autonomic tone, slowing SA node firing, or modulating neurotransmitter balance. This section covers the most common drugs women are prescribed.

Beta-Blockers: The Strongest HRV Signal

Beta-blockers are the drug class with the most consistent and largest effect on HRV. They block sympathetic input to the heart, which shifts the sympatho-vagal balance toward parasympathetic dominance. This raises SDNN and rmsSD in people with high sympathetic drive (heart failure, post-MI, hypertension) 6.

In healthy women with normal baseline HRV, beta-blockers may paradoxically lower HRV by blunting the full dynamic range of ANS response.

Specific effects by agent:

• Metoprolol succinate 50-100 mg daily: raises 24-hour SDNN by approximately 20-35 ms in women with heart failure with reduced ejection fraction 6
• Carvedilol 25 mg twice daily: alpha/beta blockade produces a different HRV fingerprint; LF power increases more than HF power compared with selective agents
• Atenolol: less CNS penetration, smaller rmsSD effect than metoprolol in head-to-head comparisons
• Propranolol: non-selective blockade; in women with anxiety-driven sympathetic excess, rmsSD gains can be substantial

If you are prescribed a beta-blocker and track HRV, expect your numbers to rise over 2-4 weeks. A persistent fall instead suggests the dose is suppressing your already-adequate vagal tone rather than correcting sympathetic overdrive.

SSRIs, SNRIs, and Antidepressants

This is an area where the data in women is thin, and extrapolation from mixed-sex trials is common.

SSRIs tend to lower HRV by increasing serotonin signaling, which has sympathomimetic downstream effects on the SA node 7. Studies of paroxetine and sertraline show rmsSD reductions of 5-15 ms in depressed populations. The clinical significance of this reduction is unclear in otherwise healthy women, but it is worth noting if you are using HRV as a recovery or resilience metric.

Venlafaxine (an SNRI) consistently reduces HRV more than SSRIs because of its norepinephrine reuptake component, which raises sympathetic tone 7.

Bupropion appears to have a smaller HRV effect than either SSRIs or SNRIs, possibly because its dopaminergic mechanism is less directly autonomic.

Tricyclic antidepressants (TCAs): these cause the largest HRV reductions of any antidepressant class, due to strong anticholinergic effects. Amitriptyline reduces rmsSD substantially and carries a mortality signal in post-cardiac-event populations. TCAs are rarely first-line in women but appear in low doses for chronic pain and off-label for perimenopausal sleep disruption.

A practical framework for women on antidepressants and tracking HRV: treat your pre-medication baseline (measured for 2 weeks before starting the drug) as your personal reference point. A drop of more than 15 ms in rmsSD sustained beyond 4 weeks is worth raising with your prescriber, especially if you have cardiovascular risk factors.

Hormonal Medications

Estrogen and progesterone are not neutral with respect to the ANS.

Combined oral contraceptives (COCs): suppress endogenous estrogen fluctuations and generally flatten the menstrual cycle's natural HRV variation. Some studies show a modest reduction in rmsSD on COCs compared with naturally cycling women, while others show no significant change. The direction of effect may depend on the progestin component, as androgenic progestins (levonorgestrel, norgestrel) appear to attenuate vagal tone more than anti-androgenic progestins (drospirenone, cyproterone) 8.

Menopausal hormone therapy (MHT): this is an area of genuine clinical interest. Estradiol increases vagal tone through cardiac muscarinic receptor upregulation. The ELITE trial and observational analyses suggest that women who initiate MHT within 10 years of menopause maintain higher HRV than non-users, though no large RCT has used HRV as a primary endpoint specifically 9. Progesterone (especially oral micronized progesterone) may have an additive positive effect on HRV through GABA-A modulation, producing a mild parasympathomimetic effect distinct from synthetic progestins.

GLP-1 receptor agonists (semaglutide, tirzepatide): these drugs modulate the vagus nerve directly. Early data from Ozempic trials and post-hoc analyses of SUSTAIN show that semaglutide raises rmsSD by approximately 3-8 ms over 26 weeks, an effect attributed partly to weight loss and partly to direct GLP-1 receptor activation on vagal afferents 10. Women with PCOS may see a larger benefit because PCOS independently lowers HRV via insulin resistance-driven sympathetic excess.

Thyroid Medications

Thyroid status directly determines resting heart rate and HRV. Over-replacement with levothyroxine, pushing free T4 to the high-normal range or suppressing TSH below 0.1 mIU/L, reliably lowers HRV by increasing sympathetic drive and shortening NN intervals. Women with differentiated thyroid cancer who require TSH suppression need to be aware that their HRV will read low even if they feel well 11.

Under-replacement (TSH above 4.5 mIU/L) also lowers HRV, through a different mechanism: reduced cardiac output and blunted baroreflex sensitivity. The optimal TSH range for maintaining HRV in symptomatic hypothyroid women is unclear from trial data; most endocrinologists target 1.0-2.5 mIU/L for symptom relief and autonomic function.

Stimulants and ADHD Medications

Amphetamines and methylphenidate raise sympathetic tone and consistently lower rmsSD. In women with ADHD (a condition whose prevalence in women has been dramatically under-estimated), this medication-induced HRV reduction can confound tracking if you are also using wearables for health monitoring. The magnitude is dose-dependent: methylphenidate 10 mg reduces rmsSD by approximately 8-12 ms, and 30-40 mg reduces it by 18-25 ms in adults 12.

Anti-Anxiety Medications

Benzodiazepines raise rmsSD acutely by enhancing GABAergic parasympathetic tone. This is real and measurable within 60 minutes of a dose. With chronic use, the effect attenuates as CNS adaptation occurs.

Buspirone: a 5-HT1A partial agonist that raises HF power modestly without the rebound effect of benzodiazepines.

Medications That Have Little or No Clinically Meaningful Effect on HRV

Not every drug you are prescribed will move the needle. The following show minimal HRV signal in controlled studies:

• Most statins (at standard doses)
• ACE inhibitors (modest HRV rise in some heart failure data, but inconsistent)
• Metformin (no direct HRV effect, though insulin sensitization may improve HRV indirectly over time)
• Standard-dose levothyroxine at a TSH of 1-2.5 mIU/L

HRV Across Women's Life Stages

Reproductive Years

Your HRV baseline in your 20s and 30s is likely the highest it will ever be. This is physiological. Estrogen upregulates cardiac muscarinic receptors and baroreflex sensitivity 2. Use this period to establish your personal reference range. Any medication started during this time that drops your rmsSD by more than 15 ms deserves discussion with your clinician.

Women with PCOS have measurably lower HRV than age- and BMI-matched controls, with studies finding rmsSD reductions of 10-20 ms tied to insulin resistance and chronic sympathetic hyperactivation 13. If you have PCOS and your HRV reads chronically low, that is not simply "your normal." It reflects a real ANS imbalance that insulin sensitization, weight management, and in some cases anti-androgen therapy can improve.

Trying to Conceive

HRV is not a validated fertility biomarker. Do not use it to time ovulation. It shifts with the cycle for reasons unrelated to fertility success. If you are using wearables that claim to predict fertile windows via HRV alone, the evidence for this specific application is weak.

Pregnancy

HRV in pregnancy follows a characteristic arc. In the first trimester, cardiac output rises and rmsSD initially increases. By the third trimester, resting heart rate climbs by 10-15 bpm, NN intervals shorten, and rmsSD falls below pre-pregnancy baseline in many women 14. This is physiological, not pathological. HRV-based algorithms in consumer wearables have not been validated in pregnancy. Interpret your numbers with caution.

Most cardiovascular medications discussed in this article require specific pregnancy risk assessment. See the dedicated pregnancy/lactation section below.

Perimenopause

The perimenopausal HRV decline is one of the least-discussed aspects of this life stage. Estrogen fluctuation drives day-to-day HRV swings that can mimic overtraining signals on wearables. Hot flashes, which represent bursts of sympathetic activation, acutely suppress rmsSD for 30-90 minutes after each episode 15. Women in perimenopause who track HRV often see unexplained low-recovery days that correlate with nighttime vasomotor symptoms rather than with fitness or sleep quality per se.

MHT, if appropriate for you, may stabilize these fluctuations by reducing vasomotor symptom frequency and restoring more consistent ANS tone.

Postmenopause

After the final menstrual period, the sex-based HRV advantage over men largely disappears. Women in postmenopause have HRV values comparable to or slightly lower than age-matched men 2. Cardiovascular risk accelerates, and HRV may have a stronger predictive value for cardiac events in this group than in younger women. This is the life stage where a 24-hour Holter-derived SDNN below 50 ms should prompt a cardiovascular risk conversation with your clinician, not just a note in a wellness app.

Pregnancy, Lactation, and Medication Safety for HRV-Altering Drugs

This section addresses medications that significantly alter HRV and their safety status in pregnancy and lactation.

Beta-blockers in pregnancy: labetalol and metoprolol are commonly used for hypertension in pregnancy and are considered relatively safe, though both cross the placenta. Neonatal bradycardia and hypoglycemia have been reported with third-trimester use. Neither is a teratogen at standard doses, but both require careful fetal monitoring near delivery 16. Atenolol is generally avoided due to fetal growth restriction concerns.

SSRIs in pregnancy: paroxetine is the only SSRI with a persistent cardiac teratogenicity signal (FDA Category D for paroxetine specifically); other SSRIs (sertraline, escitalopram) are generally preferred and are not classified as teratogens, though neonatal adaptation syndrome can occur with third-trimester use 17. Lactation transfer of sertraline is low and it is the preferred SSRI for breastfeeding women.

MHT: contraindicated in pregnancy. If you are perimenopausal and still potentially fertile, reliable contraception is required before and during MHT use. The combination of irregular cycles and MHT creates a real conception risk that is routinely under-estimated.

GLP-1 receptor agonists: semaglutide and tirzepatide are contraindicated in pregnancy. The FDA recommends discontinuing semaglutide at least 2 months before a planned conception given its long half-life 18. Women of reproductive age prescribed GLP-1 agonists should use effective contraception. Lactation data are limited; animal studies show transfer into breast milk but human data are absent.

Stimulants (amphetamine/methylphenidate): avoid in pregnancy where possible. Methylphenidate has limited human safety data; amphetamines carry risks of preterm birth and low birth weight in observational data. If ADHD treatment in pregnancy is necessary, the decision requires specialist input. Lactation transfer of methylphenidate is low, but individualized risk-benefit assessment is required.

Benzodiazepines: not recommended in pregnancy (risk of neonatal withdrawal and possible cleft palate with first-trimester exposure). Avoid in breastfeeding; transfer to breast milk can cause neonatal sedation.

Who Should Pay Attention to Medication-Driven HRV Changes

You likely benefit from HRV monitoring in relation to your medications if:

• You are a perimenopausal or postmenopausal woman starting or changing a cardiovascular drug (beta-blocker, antiarrhythmic)
• You have PCOS and are starting insulin sensitization therapy, which may improve your chronically suppressed HRV
• You are beginning or stopping an SSRI or SNRI and want an objective ANS signal alongside your mood monitoring
• You have autoimmune thyroid disease (Hashimoto's, postpartum thyroiditis) and are on levothyroxine, where dose adjustments change HRV measurably
• You are using a GLP-1 agonist and want to track autonomic improvement alongside metabolic markers

HRV monitoring adds less value if:

• You are checking a single reading and comparing it to a generic population chart without establishing your personal baseline first
• You are pregnant and using a consumer wearable's HRV algorithm (not validated in pregnancy)
• You are in an acute illness; HRV reliably drops during infection and does not reflect your medication's effect during that period

How to Measure HRV Reliably, Especially on Medications

Consistency matters more than precision of equipment. A modest accuracy wearable used the same way every morning outperforms a hospital-grade system used inconsistently.

Best practice for medication effect monitoring:

1. Measure immediately on waking, before getting up, for 5 minutes supine. Record this daily for 14 days before starting a new medication.
2. Continue daily measurement for 4-6 weeks after starting the drug. Most medication-driven HRV changes stabilize within this window.
3. Log menstrual phase (follicular, ovulatory, luteal, menstrual) to separate hormonal variation from drug effects.
4. Log sleep duration, alcohol, and acute illness, as these are the three biggest non-medication HRV confounders.
5. Report a sustained drop of more than 15 ms in rmsSD from your personal baseline to your prescribing clinician, particularly if you have cardiovascular risk factors.

A 2022 analysis of consumer wearable HRV accuracy found that Polar H10 chest strap rmsSD readings are within 1-2 ms of clinical-grade ECG in women, while optical wrist-based sensors (Apple Watch, Garmin Venu series) have wider error margins during sleep-based measurement (approximately 5-10 ms) but sufficient precision for trend tracking 19.

The Evidence Gap: What We Do Not Yet Know for Women

Women make up fewer than 35% of subjects in most antiarrhythmic and cardiovascular HRV drug trials. The specific HRV effects of many antidepressants, hormonal medications, and stimulants in women across life stages have been studied in small samples, often in premenopausal women only. Data on HRV medication effects in postmenopausal women, in women with PCOS, or during perimenopause is genuinely sparse.

As WomanRx clinical reviewer Dr. Elena Vasquez notes: "The HRV normative data most clinicians use was generated largely from male-majority cohorts. When a postmenopausal woman shows me an rmsSD of 28 ms, I cannot confidently tell her whether that is her optimal or her floor, because the sex-stratified and menopause-stratified reference intervals simply have not been built with enough precision yet."

This honesty is not a reason to dismiss HRV tracking. It is a reason to interpret your numbers in the context of your own trend rather than a single external reference point, and to advocate for more women-specific data in the HRV literature.